کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2998316 | 1180233 | 2016 | 17 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
My Approach to the Patient With Familial Hypercholesterolemia
ترجمه فارسی عنوان
رویکرد من به بیمار مبتلا به هیپرکلسترولمی خانوادگی
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
FDAPCSK9HoFHHeFHapoBASCVDCHDMTPNPC1L1HDL-CLDL-CDutch Lipid Clinic NetworkACC/AHA - ACC / AHALp(a) - Lp (a)Myocardial infarction - آنفارکتوس میوکاردApolipoprotein B - آپولیپوپروتئین BNational Lipid Association - انجمن ملی لیپیدcoronary heart disease - بیماری عروق کرونر قلبAtherosclerotic cardiovascular disease - بیماری قلبی عروقی AtheroscleroticTriglycerides - تریگلیسریدsubcutaneous - زیر جلدیFood and Drug Administration - سازمان غذا و داروLipoprotein(a) - لیپوپروتئین (a)high-density lipoprotein cholesterol - لیپوپروتئین پرچگالی یا اچدیالNla - نهFamilial hypercholesterolemia - هیپرکلسترولمی فامیلیmicrosomal triglyceride transfer protein - پروتئین انتقال تری گلیسرید میکروسمالیProprotein convertase subtilisin/kexin type 9 - پروتیکین تبدیل اساتید سوتیلیسین / نوع ککسین 9American College of Cardiology/American Heart Association - کالج آمریکایی قلب و عروق / انجمن قلب آمریکاLow-density lipoprotein cholesterol - کلسترول لیپوپروتئین با چگالی کم
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
چکیده انگلیسی
Familial hypercholesterolemia (FH), a relatively common Mendelian genetic disorder, is associated with a dramatically increased lifetime risk of premature atherosclerotic cardiovascular disease due to elevated plasma low-density lipoprotein cholesterol (LDL-C) levels. The diagnosis of FH is based on clinical presentation or genetic testing. Early identification of patients with FH is of great public health importance because preventive strategies can lower the absolute lifetime cardiovascular risk and screening can detect affected relatives. However, low awareness, detection, and control of FH pose hurdles in the prevention of FH-related cardiovascular events. Of the estimated 0.65 million to 1 million patients with FH in the United States, less than 10% carry a diagnosis of FH. Based on registry data, a substantial proportion of patients with FH are receiving no or inadequate lipid-lowering therapy. Statins remain the mainstay of treatment for patients with FH. Lipoprotein apheresis and newly approved lipid-lowering drugs are valuable adjuncts to statin therapy, particularly when the LDL-C-lowering response is suboptimal. Monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 provide an additional approximately 60% lowering of LDL-C levels and are approved for use in patients with FH. For homozygous FH, 2 new drugs that work independent of the LDL receptor pathway are available: an apolipoprotein B antisense oligonucleotide (mipomersen) and a microsomal triglyceride transfer protein inhibitor (lomitapide). This review attempts to critically examine the available data to provide a summary of the current evidence for managing patients with FH, including screening, diagnosis, treatment, and surveillance.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Mayo Clinic Proceedings - Volume 91, Issue 6, June 2016, Pages 770-786
Journal: Mayo Clinic Proceedings - Volume 91, Issue 6, June 2016, Pages 770-786
نویسندگان
Maya S. MD, PhD, Iftikhar J. MD,